CHE · Chemed Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Roto-Rooter) non-GAAP | $48.5M | second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA margin (Roto-Rooter) non-GAAP | 21.1% | second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA margin, excluding Medicare Cap non-GAAP | 18.2% | second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA, excluding Medicare Cap non-GAAP | $80.6M | second quarter of 2026 | — |
|
|
|||
| Admissions | 19,125 | second quarter of 2026 | — |
|
|
|||
| Average Daily Census (ADC) | 23,687 | second quarter of 2026 | — |
|
|
|||
| Average revenue per patient per day | $209.98 | second quarter of 2026 | — |
|
|
|||
| Gross margin (Roto-Rooter) | 50.4% | second quarter of 2026 | — |
|
|
|||
| Gross margin, excluding Medicare Cap (VITAS) non-GAAP | 23.9% | second quarter of 2026 | — |
|
|
|||
| High acuity days-of-care as % of total days of care | 2.2% | second quarter of 2026 | — |
|
|
|||
| Medicare provider numbers with projected Cap cushion of 10% or greater | 22 | full-year 2026 (as of June 30, 2026) | — |
| Net Income, excluding certain discrete items (Roto-Rooter) non-GAAP | $33.8M | second quarter of 2026 | — |
| Net Income, excluding certain discrete items (VITAS) non-GAAP | $61.3M | second quarter of 2026 | — |
| Reimbursement for high acuity care | $1,152.14 | second quarter of 2026 | — |
|
|
|||
| Reimbursement for routine home care | $188.62 | second quarter of 2026 | — |
|
|
|||
| Revenue from independent contractors | $17.1M | second quarter of 2026 | -2.0% |
|
|
|||
| Roto-Rooter branch commercial revenue | $56.8M | second quarter of 2026 | — |
|
|
|||
| Roto-Rooter branch residential revenue | $159.1M | second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $53.5M | first quarter of 2026 | — |
| Adjusted EBITDA margin non-GAAP | 22.5% | first quarter of 2026 | — |
| Net Income, excluding certain discrete items non-GAAP | $52.2M | first quarter of 2026 | — |
| Medicare Cap billing limitation accrued | $2.4M | the fourth quarter of 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CHE
this stock
Chemed Corp
|
$6.96B | +24.5% | +4.1% | — | 3.5% |
|
HCA
HCA Healthcare, Inc.
|
$89.77B | -13.3% | +7.1% | 13.9 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.87B | -4.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.57B | +34.8% | +0.9% | 10.3 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.65B | -0.2% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CHE | -3.6% | +4.5% | +11.4% | +0.1% | +24.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.0% | +0.0% | -2.4% | -3.8% | +10.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.